Hims & Hers Health (HIMS): Company Overview, Stock, Financials & Latest News

Quick Facts

Hims & Hers Health, Inc. at a glance (figures current as of early July 2026)

Ticker	HIMS (New York Stock Exchange)
Founded	November 2017, in San Francisco, California
Headquarters	San Francisco, California, United States
Founders	Andrew Dudum, Jack Abraham, Joe Spector, and Hilary Coles
CEO	Andrew Dudum, Co-founder and Chief Executive Officer
Public listing	January 2021, via a $1.6 billion SPAC merger with Oaktree Acquisition Corp
Industry	Telehealth, direct to consumer healthcare and wellness
Market capitalization	Roughly $7 billion to $10 billion, varying with daily trading
Q1 2026 revenue	Approximately $608 million, up 4 percent year over year
FY2026 revenue guidance	$2.8 billion to $3.0 billion
Subscribers	Nearly 2.6 million as of Q1 2026, up 9 percent year over year
Dividend	None paid
Key partner	Novo Nordisk, distributing branded Wegovy and Ozempic

What Is Hims & Hers Health?

Hims & Hers Health is an American telehealth and consumer wellness company that connects customers to licensed healthcare providers online and then ships prescription and over the counter treatments directly to their homes. The platform was built around removing the friction and stigma often associated with sensitive health conditions, allowing customers to complete an online consultation, receive a prescription if appropriate, and have medication delivered discreetly, all without an in person doctor visit for many conditions.

Originally focused narrowly on men’s health issues such as hair loss and erectile dysfunction under the Hims brand, and women’s health and skincare under the Hers brand, the company has since expanded into a much broader wellness platform covering dermatology, mental health, primary care, and, most significantly in recent years, medical weight loss built around GLP-1 medications. Hims & Hers operates primarily on a subscription model, with recurring revenue from millions of active subscribers making up the large majority of total sales.

In 2026, the company has been navigating a major strategic transition, shifting away from lower cost compounded versions of GLP-1 weight loss drugs toward branded medications distributed through a new partnership with pharmaceutical maker Novo Nordisk, following regulatory scrutiny of the compounding industry.

Company History

Hims & Hers Health was founded in November 2017 in San Francisco by Andrew Dudum, Jack Abraham, Joe Spector, and Hilary Coles, building on infrastructure and early funding from Atomic, a venture studio co-founded by Dudum. The company launched first as Hims, targeting men’s health concerns like hair loss and erectile dysfunction with a direct to consumer telehealth model, before launching Hers in 2018 to serve women’s wellness needs including birth control access, hair regrowth treatment, and skincare.

The company grew quickly in its early years, raising a $7 million Series A round led by Forerunner Ventures and Thrive Capital, followed by a $100 million Series C round in January 2019 that valued the business at approximately $1 billion. Hims & Hers went public in January 2021 through a merger with a special purpose acquisition company, Oaktree Acquisition Corp, led by prominent investor Howard Marks, in a deal valuing the combined company at approximately $1.6 billion.

Key milestones

Selected company history timeline

Period	Event
November 2017	Hims launches in San Francisco, founded by Andrew Dudum, Jack Abraham, Joe Spector, and Hilary Coles, initially focused on men’s health.
2018	Hers launches as a companion brand focused on women’s health, birth control access, and skincare.
January 2019	Raises a $100 million Series C round at an approximately $1 billion valuation.
January 2021	Goes public on the New York Stock Exchange through a SPAC merger with Oaktree Acquisition Corp, valuing the combined company at approximately $1.6 billion.
2022 to 2024	Expands aggressively into weight loss, mental health, and dermatology, building out a personalized subscription platform and growing its subscriber base into the millions.
2024 to early 2025	Launches compounded GLP-1 weight loss treatments during a period of branded drug shortages, driving explosive subscriber and revenue growth, while also drawing regulatory and legal scrutiny.
March 2026	Signs a distribution partnership with Novo Nordisk to offer branded Wegovy and Ozempic on its platform, agreeing to cease promotion of compounded GLP-1 alternatives, resolving an earlier legal dispute with the drugmaker.
2026	Continues international expansion, including the acquisition of digital health company Eucalyptus, extending Hims & Hers into markets including Japan, Australia, Canada, Germany, and the United Kingdom.

Founders

Hims & Hers Health was founded by a team of four co-founders with backgrounds in venture building and startup creation.

The company’s founding team built Hims & Hers within Atomic’s venture studio model, which provided shared operational resources and capital in its earliest stages, a structure that allowed the company to scale its direct to consumer telehealth platform quickly across all 50 states in its first several years.

CEO

Andrew Dudum has served as Chief Executive Officer of Hims & Hers Health since co-founding the company in 2017. Before Hims & Hers, Dudum co-founded Atomic, a startup studio and investment fund where he played a role in developing multiple companies as a general partner. Under Dudum’s leadership, Hims & Hers has expanded from a narrowly focused men’s health brand into a broad, multi category wellness platform, guided the company through its 2021 public listing, and led its recent strategic pivot into branded GLP-1 weight loss medications through the company’s 2026 partnership with Novo Nordisk. Dudum has also been a vocal public figure on issues facing the telehealth and digital health industry, including regulatory scrutiny of compounded medications.

Headquarters

Hims & Hers Health is headquartered in San Francisco, California, reflecting its origins within the city’s startup and venture capital ecosystem. The company operates as a direct to consumer digital platform rather than a network of physical clinics, relying on a nationwide network of licensed medical providers, pharmacy partners, and fulfillment centers to deliver care and products across all 50 states. Following its 2026 acquisition of digital health company Eucalyptus, Hims & Hers has also expanded its operational footprint internationally, supporting customers in the United Kingdom, Canada, Germany, Ireland, France, Spain, Australia, and Japan.

Business Segments

Hims & Hers Health operates as a single consumer health and wellness platform, with revenue generated across several major treatment categories.

Products and Services

Hims & Hers delivers its treatments through a subscription based telehealth platform combining online consultations, digital prescriptions, and direct to consumer fulfillment.

• Online medical consultations: Access to licensed healthcare providers through the Hims & Hers website and mobile app, enabling diagnosis and prescription for a range of conditions without an in person visit.
• Weight Loss Membership: A subscription program, starting at $39 for the first month, that provides access to GLP-1 medications, including branded Wegovy and Ozempic through the Novo Nordisk partnership, alongside ongoing virtual care.
• Hair and skin treatments: Prescription and over the counter treatments for hair loss and skincare conditions, sold under both the Hims and Hers brand names.
• Sexual health treatments: Prescription medications for erectile dysfunction and other sexual health conditions, part of the original Hims product lineup.
• Laboratory testing services: At home laboratory testing to measure a range of biomarkers, supporting more personalized treatment recommendations across the platform.
• Hims & Hers Benefits: An expanding partner network offering additional wellness related discounts and services to subscribers, part of the company’s push to deepen member engagement beyond core medical treatments.

Revenue Breakdown

Hims & Hers generates the substantial majority of its revenue from recurring online subscriptions, with weight loss treatments increasingly central to the company’s overall growth trajectory even as the business model within that category has shifted.

Within its subscriber base of nearly 2.6 million, monthly online revenue per average subscriber fell to $80 in the first quarter of 2026, down from $85 a year earlier, reflecting both the shift away from higher priced compounded GLP-1 offerings and a broader mix shift across treatment categories. Management has said that roughly 90 percent of recurring revenue comes from its existing subscriber base, underscoring the importance of retention, with about 82 percent of subscribers remaining active beyond the three month mark. Following the March 2026 introduction of branded Wegovy on the platform, the company fulfilled more than 125,000 Wegovy shipments within the first six weeks and said it was on track to add more than 100,000 new weight loss subscribers per month.

Financial Performance

Hims & Hers’ financial results in early 2026 reflect a deliberate, near term disruptive transition away from compounded GLP-1 medications toward a branded, partnership based weight loss model.

Selected first quarter 2026 financial results

Metric	Q1 2026	Year over year change
Revenue	Approximately $608 million	Up 4 percent
Net loss	Approximately $92 million	Compared to net income in the prior year period
Gross margin	65 percent	Down from 73 percent
Adjusted EBITDA	$44.3 million	Down from $91.1 million
Subscribers	Nearly 2.6 million	Up 9 percent
Monthly revenue per average subscriber	$80	Down from $85

For the second quarter of 2026, Hims & Hers guided for revenue of $680 million to $700 million and adjusted EBITDA of $35 million to $55 million. For the full year, management raised revenue guidance to a range of $2.8 billion to $3.0 billion, representing growth of 19 percent to 28 percent from 2025 levels, and set updated adjusted EBITDA guidance of $275 million to $350 million. The company has also reiterated longer term 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, reflecting continued confidence in its multi year growth trajectory despite the near term disruption from its GLP-1 transition.

Stock Information

Hims & Hers Health went public in January 2021 through a merger with a special purpose acquisition company, Oaktree Acquisition Corp, led by investor Howard Marks, valuing the combined company at approximately $1.6 billion. The stock has since been one of the more volatile names in the digital health sector, driven by rapid swings in sentiment around its weight loss business and related regulatory developments.

Snapshot trading data as of early July 2026

Recent share price	Roughly $36 to $40, varying by session
Market capitalization	Approximately $7 billion to $10 billion depending on the trading day
52 week range	Approximately $13.74 to $70.43
Beta	Approximately 1.25, indicating higher volatility relative to the broader market
Price to earnings ratio	Not meaningful on a trailing basis, reflecting a recent quarterly net loss
Analyst consensus	Mixed, ranging from Hold to Buy, with price targets recently raised by several firms into the $36 to $40 range following the Novo Nordisk partnership
Next earnings date	Expected August 10, 2026

HIMS shares have moved sharply on individual news events throughout 2026, including a more than 40 percent single day surge following the announcement of the Novo Nordisk partnership in March, a roughly 13 percent decline following its first quarter earnings report in May, and a steady climb through June and early July as analysts including BofA and Canaccord raised price targets on improving sales trends and reduced legal and regulatory risk. Several banks have issued Street high price targets around $40, while others maintain more cautious Hold ratings tied to execution risk and valuation concerns.

Dividends

Hims & Hers Health does not pay a dividend. As a growth focused consumer health company still investing heavily in subscriber acquisition, international expansion, and its transitioning weight loss business, the company is directing its cash flow toward growth initiatives rather than shareholder distributions. This is standard for a company at Hims & Hers’ stage of growth, and investors in HIMS are generally positioned for capital appreciation tied to subscriber growth and margin improvement rather than income.

Competitors

Hims & Hers competes in the fast growing direct to consumer telehealth and digital health market, facing competition from both dedicated telehealth platforms and traditional healthcare and pharmaceutical companies entering the space.

Selected Hims & Hers Health competitors

Competitor	Positioning
Ro (Roman and Rory)	A privately held direct to consumer telehealth company competing directly across men’s health, women’s health, and weight loss categories with a similar subscription model.
LifeMD	A publicly traded telehealth company offering weight loss, primary care, and other subscription based virtual care services to a similar consumer base.
Teladoc Health	A larger, more established telehealth provider with a broader focus on employer and health system partnerships rather than Hims & Hers’ direct to consumer brand approach.
Noom	A weight management and behavior change platform that has expanded into GLP-1 adjacent coaching and telehealth services, competing for weight loss focused subscribers.
Novo Nordisk and Eli Lilly direct channels	The pharmaceutical manufacturers behind branded GLP-1 drugs Wegovy, Ozempic, and Zepbound have increasingly launched their own direct to consumer sales channels, creating both a partnership opportunity and a potential long term competitive threat to telehealth intermediaries like Hims & Hers.

Hims & Hers’ relationship with Novo Nordisk illustrates the complex, dual natured competitive dynamic in this market: pharmaceutical manufacturers are simultaneously essential supply partners for branded medications and potential long term competitors as they build out their own direct to consumer distribution capabilities. Hims & Hers has positioned its broad multi category platform, large existing subscriber base, and consumer facing brand identity as key differentiators against both dedicated telehealth rivals and pharmaceutical manufacturers’ direct channels.

Recent News

• July 2026, new receivables financing facility: Hims & Hers established a new $400 million receivables facility in partnership with JPMorgan, unlocking additional working capital to support its growth initiatives.
• July 2026, analyst price target increases: Bank of America raised its price target on HIMS shares to $36, and Canaccord Genuity raised its target to a Street high $40, both citing improving sales trends and reduced regulatory risk following the Novo Nordisk partnership.
• May 2026, first quarter earnings and guidance raise: Hims & Hers reported revenue of approximately $608 million, up just 4 percent year over year, and a net loss of about $92 million as it transitioned toward branded GLP-1 products, while raising full year revenue guidance to $2.8 billion to $3.0 billion.
• March 2026, Novo Nordisk partnership announced: Hims & Hers signed a distribution agreement with Novo Nordisk to offer branded Wegovy and Ozempic on its platform in exchange for ceasing promotion of compounded GLP-1 alternatives, resolving a prior legal dispute and sending shares up more than 40 percent over several trading days.
• 2026, international expansion continues: Hims & Hers completed its acquisition of digital health company Eucalyptus, extending its platform into Japan and strengthening its presence in Australia, Canada, Germany, and the United Kingdom, part of a broader push into international markets.
• 2026, Canadian generic semaglutide launch: Hims & Hers began offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic, through its platform.
• Ongoing, securities litigation from 2025: Hims & Hers has faced multiple shareholder securities lawsuits stemming from allegations of deceptive marketing practices tied to its earlier compounded GLP-1 business, a legal overhang that has continued to draw investor attention even as the company’s relationship with Novo Nordisk has reduced some of the underlying regulatory risk.

Frequently Asked Questions

Back to top